269 related articles for article (PubMed ID: 32398047)
1. Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).
Dąbrowski R; Syska P; Mączyńska J; Farkowski M; Sawicki S; Kubaszek-Kornatowska A; Michałek P; Kowalik I; Szwed H; Hryniewiecki T
Trials; 2020 May; 21(1):397. PubMed ID: 32398047
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).
Farkowski MM; Maciag A; Dabrowski R; Pytkowski M; Kowalik I; Szwed H
Trials; 2012 Sep; 13():162. PubMed ID: 22967497
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
Maciag A; Farkowski MM; Chwyczko T; Beckowski M; Syska P; Kowalik I; Pytkowski M; Wozniak J; Dabrowski R; Szwed H
Europace; 2017 Oct; 19(10):1637-1642. PubMed ID: 28339554
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
Beatch GN; Mangal B
BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
7. [Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].
Fetsch T; Burschel G; Breithardt G; Engberding R; Koch HP; Lukl J; Trappe HJ; Treese N
Z Kardiol; 1999 Mar; 88(3):195-207. PubMed ID: 10355070
[TBL] [Abstract][Full Text] [Related]
8. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
9. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.
Okishige K; Nishizaki M; Azegami K; Igawa M; Yamawaki N; Aonuma K;
Am Heart J; 2000 Sep; 140(3):e13. PubMed ID: 10966544
[TBL] [Abstract][Full Text] [Related]
10. Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation.
Cybulski J; Kułakowski P; Budaj A; Danielewicz H; Maciejewicz J; Kawka-Urbanek T; Ceremuzyński L
Clin Cardiol; 2003 Jul; 26(7):329-35. PubMed ID: 12862299
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.
Macchia A; Grancelli H; Varini S; Nul D; Laffaye N; Mariani J; Ferrante D; Badra R; Figal J; Ramos S; Tognoni G; Doval HC;
J Am Coll Cardiol; 2013 Jan; 61(4):463-468. PubMed ID: 23265344
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
[TBL] [Abstract][Full Text] [Related]
13. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
14. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.
Nodari S; Triggiani M; Campia U; Manerba A; Milesi G; Cesana BM; Gheorghiade M; Dei Cas L
Circulation; 2011 Sep; 124(10):1100-6. PubMed ID: 21844082
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial.
Ciszewski J; Maciag A; Kowalik I; Syska P; Lewandowski M; Farkowski MM; Borowiec A; Chwyczko T; Pytkowski M; Szwed H; Sterlinski M
Trials; 2014 Oct; 15():386. PubMed ID: 25281275
[TBL] [Abstract][Full Text] [Related]
16. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation.
Dąbrowski R; Szwed H
Cardiol J; 2012; 19(3):223-9. PubMed ID: 22641540
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.
Hohnloser SH; Dorian P; Straub M; Beckmann K; Kowey P
J Am Coll Cardiol; 2004 Jul; 44(1):99-104. PubMed ID: 15234416
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
Bellandi F; Simonetti I; Leoncini M; Frascarelli F; Giovannini T; Maioli M; Dabizzi RP
Am J Cardiol; 2001 Sep; 88(6):640-5. PubMed ID: 11564387
[TBL] [Abstract][Full Text] [Related]
20. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
Singh BN; Mody FV; Lopez B; Sarma JS
Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
